tirzepatide in a vial Compounded GLP-1 - Semaglutide & Tirzepatide 7.5MG Injection Package -

2019 Jun Alejandro A Nava-Ocampo, Aleksandra Pastrak, Tony Cruz, Gideon Koren

Material changes will be communicated through the Site or by email where appropriate

Despite these challenges, CSC-targeted therapies are gradually progressing toward clinical trials, with novel strategies such as pathway inhibitors (Notch, Hedgehog, Wnt, PI3K/AKT/mTOR), immune-based therapies (CAR-T cells and cancer vaccines), and synthetic biology approaches (gene circuits, OVs) showing promising preclinical results

By week 36, that increased to 21.1%

In a 2025 study published in Obesity Medicine , 52% of patients who discontinued GLP-1 therapy cited adverse effects as the main reason